Yervoy (ipilimumab) is a checkpoint‑inhibitor that can unleash a powerful immune response against cancer, but that same immune activation can also target normal tissues. When serious (grade 3–4) immune‑related adverse events (irAEs) arise, the usual strategy is to stop the drug, start high‑dose steroids, and step‑up therapy if needed. Below is a quick‑reference guide that summarizes what’s typically done for the most common serious side effects.
| Organ system | Typical serious irAE | First‑line management | If refractory or severe | Key points |
|------------------|--------------------------|---------------------------|----------------------------|----------------|
| Gastrointestinal (colitis) | Diarrhea, abdominal pain, blood/fat‑in‑stool | • Hold ipilimumab.
• Prednisone 1‑2 mg/kg/day (or methylprednisolone 1 mg/kg IV).
• Hydration, anti‑diarrheals (loperamide)
• Oral/IV antibiotics if infection suspected | • If no improvement in 48–72 h, add infliximab 5 mg/kg (or 10 mg/kg if high‑grade).
• If still refractory, consider mycophenolate mofetil. | • Severe colitis → bowel perforation risk → urgent imaging. |
| Hepatotoxicity (hepatitis) | Elevated ALT/AST, jaundice | • Hold ipilimumab.
• Prednisone 1 mg/kg/day (or methylprednisolone 1 mg/kg IV). | • If no improvement in 3–5 days, consider adding mycophenolate mofetil or infliximab (rare).
• In extreme cases, plasma exchange or liver transplant. | • Monitor LFTs every 2–3 days. |
| Endocrinopathies (thyroid, adrenal, pituitary, diabetes) | Hypothyroidism, hyperthyroidism, adrenal insufficiency, new‑onset diabetes | • Replace hormone as needed (levothyroxine, hydrocortisone, insulin).
• Hold ipilimumab if adrenal insufficiency. | • If adrenal crisis or refractory hyperglycemia → high‑dose steroids. | • Endocrine irAEs are often permanent; lifelong monitoring. |
| Pulmonary (pneumonitis) | Cough, dyspnea, infiltrates | • Hold ipilimumab.
• Prednisone 1–2 mg/kg/day (or methylprednisolone 1 mg/kg IV).
• Oxygen support if needed. | • If no improvement in 48–72 h, add infliximab 5 mg/kg or mycophenolate. | • Pulmonary toxicity can be life‑threatening; early CT imaging essential. |
| Dermatologic (rash, vitiligo, pruritus) | Severe rash, blistering, bullous lesions | • Hold ipilimumab.
• High‑dose steroids (prednisone 1 mg/kg).
• Topical steroids, antihistamines. | • If not improving → infliximab. | • Skin toxicity often reversible but can be disfiguring. |
| Renal (interstitial nephritis) | Rising creatinine, hematuria | • Hold ipilimumab.
• Prednisone 1 mg/kg/day. | • If no response → mycophenolate mofetil or infliximab. | • Early nephrology referral recommended. |
| Neurologic (myasthenia gravis, neuropathy) | Weakness, dysphagia | • Hold ipilimumab.
• High‑dose steroids.
• Plasmapheresis or IVIG if severe. | • Consider mycophenolate or rituximab if refractory. | • Neurologic irAEs can be fatal; immediate evaluation. |
Practical steps for clinicians
1. Early detection – Patients should report new symptoms promptly. Routine labs (CBC, LFTs, CMP, TSH) are often done every 2–4 weeks during therapy.
2. Grading – Use CTCAE v5.0 to assign severity. Grade 3–4 events trigger the above approach.
3. Steroid taper – After 2–4 weeks of improvement, taper prednisone slowly (e.g., 0.5 mg/kg every 1–2 weeks) to avoid rebound flare.
4. Re‑initiation – Once the irAE is grade ≤ 1 and steroids are < 10 mg prednisone equivalent daily, some clinicians may consider re‑starting ipilimumab (often with close monitoring).
5. Multidisciplinary care – Involve gastroenterology, endocrinology, pulmonology, nephrology, or neurology as needed.
Patient‑friendly take‑away
- Stop Yervoy if you have severe diarrhea, high‑grade rash, breathing trouble, jaundice, or new hormone problems.
- Start steroids as directed; they are the cornerstone of treatment.
- Follow-up closely; your doctor may need to repeat tests and possibly add other medicines (infliximab, mycophenolate).
- Never self‑stop or adjust medications without consulting your oncology team.
If you’re a patient experiencing these symptoms, contact your oncologist or nearest emergency department right away. Timely intervention dramatically improves outcomes.